Article Details
Retrieved on: 2024-12-15 22:09:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Oryzon Genomics’ drug Iadademstat, using GlobalData's business intelligence and risk-adjusted net present value (rNPV) model to assess its valuation. It relates to tags by evaluating clinical trials, valuation, and fundamental analysis in drug discovery.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here